Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg)
co-administered with all approved doses of atorvastatin in a double-blind comparison with
placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary
hypercholesterolemia. The main objective is to evaluate the effects of the association
AVE5530+atorvastatin on LDL-C level reduction after 12 weeks of treatment. The effects of
AVE5530+atorvastatin on other lipid parameters will be assessed as secondary objectives